scholarly journals A machine learning model for the prediction of drug permeability across the Blood-Brain Barrier: a comparative approach

2020 ◽  
Author(s):  
Ralph Saber ◽  
Rami Mhanna ◽  
Sandy Rihana

Abstract Background: Drug permeability across the blood-brain barrier (BBB) is a critical challenge for successful drug discovery which has led to multiple efforts to develop in silico predictive models. Most of the in silico models are based on the molecular descriptors of the drugs. In this work, we compare the ability of sequential feature selection and genetic algorithms in selecting the most relevant descriptors and hence enhancing the permeability prediction accuracy.Methods: Five different classifiers were initially trained on a dataset using eight molecular descriptors. Then, sequential feature selection and genetic algorithms were performed separately and the same classifiers were trained using the descriptors chosen by each algorithm.Results: The highest overall accuracy obtained without feature selection was 94.98%. This accuracy increased with sequential feature selection and genetic algorithms on multiple classifiers. However, the highest accuracy (96.23%) was obtained after performing genetic algorithm on the feature vector. Moreover, genetic algorithm with a fitness function based on the performance of a support vector machine led to an increase in the accuracy of all the tested classifiers unlike sequential feature selection.Conclusions: The findings show that genetic algorithm is a more robust approach than sequential feature selection in choosing the most relevant molecular descriptors involved in the permeability across the blood-brain barrier. The results also highlight the importance of the polar surface area of drugs in crossing the BBB.

2018 ◽  
Vol 25 (9) ◽  
pp. 1073-1089 ◽  
Author(s):  
Santiago Vilar ◽  
Eduardo Sobarzo-Sanchez ◽  
Lourdes Santana ◽  
Eugenio Uriarte

Background: Blood-brain barrier transport is an important process to be considered in drug candidates. The blood-brain barrier protects the brain from toxicological agents and, therefore, also establishes a restrictive mechanism for the delivery of drugs into the brain. Although there are different and complex mechanisms implicated in drug transport, in this review we focused on the prediction of passive diffusion through the blood-brain barrier. Methods: We elaborated on ligand-based and structure-based models that have been described to predict the blood-brain barrier permeability. Results: Multiple 2D and 3D QSPR/QSAR models and integrative approaches have been published to establish quantitative and qualitative relationships with the blood-brain barrier permeability. We explained different types of descriptors that correlate with passive diffusion along with data analysis methods. Moreover, we discussed the applicability of other types of molecular structure-based simulations, such as molecular dynamics, and their implications in the prediction of passive diffusion. Challenges and limitations of experimental measurements of permeability and in silico predictive methods were also described. Conclusion: Improvements in the prediction of blood-brain barrier permeability from different types of in silico models are crucial to optimize the process of Central Nervous System drug discovery and development.


2017 ◽  
Vol 2 ◽  
pp. 20-27 ◽  
Author(s):  
Sergey Shityakov ◽  
Norbert Roewer ◽  
Jens-Albert Broscheit ◽  
Carola Förster

2003 ◽  
Vol 22 (7) ◽  
pp. 745-753 ◽  
Author(s):  
Meritxell Teixidó ◽  
Ignasi Belda ◽  
Xavier Roselló ◽  
Sonia González ◽  
Myriam Fabre ◽  
...  

Author(s):  
Krishnapriya Madhu Varier ◽  
Sumathi Thangarajan ◽  
Arulvasu Chinnasamy ◽  
Gopalsamy Balakrishnan ◽  
Renjith Paulose

<p><strong>Objective: </strong>Parkinson’s disease (PD) is a leading cause of mental disability and death worldwide. Even though there are many advances in drug development against PD, a potent low dosage drug with fewer side effects are still in its nursery. This is a pioneer <em>in silico</em> attempt to test the anti-PD actions of esculin and hinokitol to act novel drugs.</p><p><strong>Methods: </strong>In this study, using Auto dock tools 4.2, esculin and hinokitol (β-Thujaplicin) were predicted for its inhibitory actions with Alpha-Synuclein (AS) Apo site, Dopamine D3 Receptor (D3R), Glycogen Synthase Kinase-3 Beta (GSK3β), Mono Oxidase B (MAO-B), Parkin and Tyrosine 3-Hydroxylase (TH) with levodopa standard. The reliability of the 3D predicted model of these proteins were analysed using RAMPAGE. Further, the blood-brain barrier (BBB) crossing ability of the natural compounds were analysed using cbligand. The <em>In silico </em>ADME (Absorption, Distribution, Metabolism, Excretion) properties of esculin and hinokitol were compared with that of levodopa using molinspiration and admetSAR @ LMMD software.<strong></strong></p><p><strong>Results: </strong>The predictions were that hinokitol, being blood-brain barrier positive (BBB+) with fewer side effects could be a potent anti-PD drug than esculin as it proved to be blood-brain barrier negative (BBB-). Hinokitol was predicted to be good inhibitors of AS, MAO-B and Parkin.</p><p><strong>Conclusion: </strong>The study revealed that hinokitol could be a potent anti-PD drug, being BBB+. Hinokitol was additionally predicted as a good inhibitor of AS, MAO-B and Parkin than levodopa standard.</p><p> </p>


Sign in / Sign up

Export Citation Format

Share Document